Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
2.
BMC Geriatr ; 12: 69, 2012 Nov 13.
Artigo em Inglês | MEDLINE | ID: mdl-23148576

RESUMO

BACKGROUND: An increased risk of venous thromboembolism has been reported in patients treated with non-steroidal anti-inflammatory drugs (NSAIDs). We describe a case of acute portal vein thrombosis (PVT) in a hepatitis C virus (HCV)-positive elderly patient following administration of indomethacin. CASE PRESENTATION: A 79-year-old HCV-positive man was hospitalized for severe abdominal pain, nausea and vomiting, 15 days after starting indomethacin for back pain. Clinical signs and imaging evaluations disclosed a picture of PVT. Indomethacin was discontinued, and the patient was started on fondaparinux and antithrombin. He was discharged 15 days later due to improvement of his clinical conditions. Thirty days later, a follow-up ultrasound did not show appreciable signs of PVT. The time elapsing between the start of analgesic therapy and PVT onset suggests a role of indomethacin as the triggering agent. Indomethacin could have precipitated PVT by a combination of at least two detrimental mechanisms: 1) direct action on liver vascular endothelium by inhibition of prostacyclin biosynthesis; 2) damage to the intestinal mucosa, followed by inflammatory and pro-coagulant activation of portal endothelium upon exposure to bacterial endotoxins. CONCLUSIONS: This case can be of interest to physicians, who should exert caution when prescribing NSAIDs for inflammatory pain in patients with background inflammatory dysfunctions of the portal vein endothelium.


Assuntos
Hepacivirus , Hepatite C Crônica , Indometacina/efeitos adversos , Veia Porta/patologia , Trombose Venosa/induzido quimicamente , Trombose Venosa/diagnóstico , Doença Aguda , Idoso , Hepatite C Crônica/diagnóstico , Hepatite C Crônica/tratamento farmacológico , Humanos , Masculino , Veia Porta/efeitos dos fármacos , Veia Porta/virologia , Trombose Venosa/virologia
3.
Shock ; 24(5): 407-11, 2005 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-16247324

RESUMO

The mechanism of shock in patients with dengue hemorrhagic fever (DHF) has not yet been fully understood. In this study, we investigated the possibility of splanchnic venous pooling as a contributor for circulatory dysfunction in these patients. Ultrasonographic studies of portal vein and inferior vena cava were done in 45 patients with serologically or PCR-confirmed diagnosis of dengue virus infection. The size of portal vein and inferior vena cava, mean blood flow velocity in the right portal vein, and modified portal vein congestion index were compared between patients with dengue fever (DF, n = 20), DHF without shock (n = 14), and dengue shock syndrome (DSS, n = 11) during the toxic stage, convalescent stage, and at follow-up. The portal vein was significantly more dilated in patients with shock (DSS) than DHF without shock and than DF during the toxic and convalescent stages (P < 0.05), but not at follow-up. The change in the size of inferior vena cava followed the opposite trend (not statistically significant). Portal vein blood flow velocity was lower and congestion index was higher in shock cases (DSS) than DHF without shock and than DF at toxic and convalescent stages (P < 0.01). The differences disappeared at follow-up. Hepatosplanchnic venous pooling and/or dysfunction occur and correlate with the severity of circulatory derangement and shock in patients with DHF. The cause(s) and significance of hepatosplanchnic circulatory dysfunction in DHF and possibly other viral hepatic diseases deserve further study.


Assuntos
Hepatopatias/complicações , Hepatopatias/fisiopatologia , Fígado/virologia , Veia Porta/patologia , Dengue Grave/complicações , Choque/complicações , Veia Cava Inferior/patologia , Adolescente , Criança , Pré-Escolar , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Masculino , Reação em Cadeia da Polimerase , Veia Porta/diagnóstico por imagem , Veia Porta/virologia , Baço/irrigação sanguínea , Fatores de Tempo , Ultrassonografia , Veia Cava Inferior/diagnóstico por imagem , Veia Cava Inferior/virologia
4.
Mol Ther ; 11(1): 26-34, 2005 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-15585403

RESUMO

Lentiviral vectors can stably transduce dividing and nondividing cells in vivo and are best suited to long-term correction of inherited liver diseases. Intraportal administration of lentiviral vectors expressing green fluorescent protein (Lenti-GFP) in mice resulted in a higher transduction of nonparenchymal cells than hepatocytes (7.32 +/- 3.66% vs 0.22 +/- 0.08%, respectively). Therefore, various treatments were explored to increase lentiviral transduction of hepatocytes. Lenti-GFP was injected into the common bile duct, which led to transduction of biliary epithelium and hepatocytes at low efficiency. Transient removal of the sinusoidal endothelial cell layer by cyclophosphamide to increase accessibility to hepatocytes did not improve hepatocyte transduction (0.42 +/- 0.36%). Inhibition of Kupffer cell function by gadolinium chloride led to a significant decrease in GFP-positive nonparenchymal cells (2.15 +/- 3.14%) and a sevenfold increase in GFP-positive hepatocytes compared to nonpretreated mice (1.48 +/- 2.01%). These findings suggest that sinusoidal endothelial cells do not significantly limit lentiviral transduction of hepatocytes, while Kupffer cells sequester lentiviral particles thereby preventing hepatocyte transduction. Therefore, the use of agents that inhibit Kupffer cell function may be important for lentiviral vector treatment of liver disease.


Assuntos
Hepatócitos/virologia , Células de Kupffer/fisiologia , Lentivirus/genética , Lentivirus/fisiologia , Transdução Genética/métodos , Alanina Transaminase/metabolismo , Animais , Ductos Biliares/virologia , Linhagem Celular , Ciclofosfamida/farmacologia , Células Endoteliais/patologia , Células Endoteliais/virologia , Gadolínio/farmacologia , Hepatócitos/enzimologia , Hepatócitos/metabolismo , Células de Kupffer/patologia , Lentivirus/efeitos dos fármacos , Fígado/enzimologia , Fígado/metabolismo , Fígado/ultraestrutura , Fígado/virologia , Masculino , Camundongos , Microscopia Eletrônica , Fagocitose , Reação em Cadeia da Polimerase , Veia Porta/virologia
5.
J Hepatol ; 31(5): 913-20, 1999 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-10580590

RESUMO

BACKGROUND/AIM: Chronic rejection is an important cause of graft loss following liver transplantation. A number of risk factors for chronic rejection have been identified previously, albeit inconsistently. These include cytomegalovirus infection detected by a number of different techniques, including immunohistochemical staining and in situ hybridisation of liver grafts. However, tissue-based techniques for the detection of CMV have not been applied to grafts lost to conditions other than chronic rejection. The purpose of this study was to investigate the relationship between the presence of cytomegalovirus infection detected by in situ hybridisation and immunohistochemistry with respect to graft outcome, the presence of cytomegalovirus infection detected by other techniques and in addition, the type of infected cell. METHODS: The 29 patients studied included 15 patients who lost their primary liver graft to chronic rejection in 8 cases, to hepatic artery thrombosis in 4 cases and to causes other than chronic rejection or hepatic artery thrombosis in 3 further cases. In each case, sections containing septal or large ducts and vessels were selected (usually blocks) since these may be more representative. Needle biopsies from 14 further patients who ultimately achieved satisfactory graft function served as control tissue. Of these, ten had evidence of cytomegalovirus infection at the time of study by serum/urine PCR, DEAFF testing or seroconversion, while 4 patients had no evidence of cytomegalovirus infection according to these techniques. RESULTS: Cytomegalovirus infection was detected in the liver of 12 of the 29 patients. These included 8/15 grafts lost, which comprised 3/8 with chronic rejection, 2/3 with hepatic artery thrombosis and 3/4 with grafts lost to other causes, as well as 4/14 who retained grafts. CMV was detected most commonly in association with symptomatic infection and notably was detected only by in situ hybridisation in two cases. Predominant cell types that contained cytomegalovirus were hepatocytes and mononuclear cells. However, bile duct epithelial cells, hepatic artery endothelial cells and portal venous endothelial cells also contained cytomegalovirus in some cases. CONCLUSIONS: These data support previous studies that cytomegalovirus infection is detectable in patients with chronic rejection and are consistent with the theory that CMV is involved in chronic rejection. However, cytomegalovirus infection was detected in explanted grafts lost to conditions other than chronic rejection, and the association may not be causal but a consequence of graft injury.


Assuntos
Ductos Biliares/virologia , Infecções por Citomegalovirus/patologia , Citomegalovirus/isolamento & purificação , Endotélio Vascular/virologia , Rejeição de Enxerto/patologia , Transplante de Fígado/patologia , Biópsia por Agulha , Doença Crônica , Infecções por Citomegalovirus/complicações , Células Epiteliais/virologia , Rejeição de Enxerto/complicações , Rejeição de Enxerto/virologia , Artéria Hepática/virologia , Humanos , Hibridização In Situ , Veia Porta/virologia , Reoperação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA